Sana Biotechnology Inc SANA

Healthcare Biotechnology

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

NDAQ:SANA - Post by User

Sana Biotechnology Inc

<< Previous

Bullboard Posts

Post by whytestockson Aug 09, 2024 1:02pm

36 Views

Post# 36171658

Buy Recommendation Issued On SANA By Citigroup

Breaking News: $SANA Buy Recommendation Issued On SANA By Citigroup2024-08-09 07:30:08 ET Citigroup analyst issues BUY recommendation for SANA on August 9, 2024 06:00AM ET. The previous analyst recommendation was Buy. SANA was trading at $4.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...SANA - Buy Recommendation Issued On SANA By Citigroup

<< Previous

Bullboard Posts

Who, why, and what of the great "Crypto Surge"